Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7,840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of nivolumab and ipilimumab with or without chemotherapy for unresectable non-small cell lung cancer: a multicenter retrospective observational study.
Sumi T, Nagano Y, Yokoo K, Ishikawa T, Nishikiori H, Honjo O, Kudo S, Yamazoe M, Kondoh S, Shioya M, Otsuka M, Hashimoto M, Yabe H, Tanaka Y, Sudo Y, Yanagi M, Takahashi M, Chiba H. Sumi T, et al. Among authors: ishikawa t. Cancer Immunol Immunother. 2025 Jan 3;74(2):39. doi: 10.1007/s00262-024-03890-4. Cancer Immunol Immunother. 2025. PMID: 39751674 Free PMC article.
Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor.
Murao K, Mori Y, Takahashi Y, Ishikawa T, Asai Y, Kobayashi T, Ikeda K, Kuronuma K, Magara K, Fujita H, Hirohashi Y, Takasawa A, Chiba H. Murao K, et al. Among authors: ishikawa t. Intern Med. 2022 Nov 1;61(21):3259-3264. doi: 10.2169/internalmedicine.8916-21. Epub 2022 Apr 9. Intern Med. 2022. PMID: 35400698 Free PMC article.
Management of anti-melanoma differentiation-associated gene 5 antibody-induced refractory dermatomyositis complicated by interstitial pneumonia using tofacitinib and its outcomes: a case report.
Imai Y, Yorozuya T, Hatakeyama T, Nishimaki T, Takahashi T, Ishikawa T, Kondoh S, Asai Y, Mori Y, Saito A, Nishikiori H, Hosaka M, Chiba H. Imai Y, et al. Among authors: ishikawa t. J Med Case Rep. 2024 Sep 28;18(1):471. doi: 10.1186/s13256-024-04793-9. J Med Case Rep. 2024. PMID: 39334485 Free PMC article.
Resected thymic large cell neuroendocrine carcinoma: report of a case.
Domen H, Hida Y, Sato M, Takahashi H, Ishikawa T, Shionoya Y, Hashimoto M, Nishiyama K, Aoki Y, Inoko K, Furukawa S, Ichinokawa K, Yamada H. Domen H, et al. Among authors: ishikawa t. Surg Case Rep. 2018 Nov 16;4(1):133. doi: 10.1186/s40792-018-0540-2. Surg Case Rep. 2018. PMID: 30446840 Free PMC article.
Survival Outcomes Associated With Radiological Progressive Disease Subtypes in Patients With Atezolizumab and Bevacizumab-Treated HCC.
Matono T, Tada T, Kumada T, Hiraoka A, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Nishikawa H, Tanaka K, Tsuji K, Ishikawa T, Tajiri K, Koshiyama Y, Toyoda H, Ogawa C, Hatanaka T, Kakizaki S, Kawata K, Ohama H, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Nishimura T, Imai M, Kosaka H, Naganuma A, Aoki T, Kuroda H, Yata Y, Nakamura Y, Yoshida O, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M; Real‐life Practice Experts for HCC (RELPEC) Study Group; Hepatocellular Carcinoma Experts from 48 clinics in Japan (HCC 48) Group. Matono T, et al. Among authors: ishikawa t. J Gastroenterol Hepatol. 2025 Jan 22. doi: 10.1111/jgh.16884. Online ahead of print. J Gastroenterol Hepatol. 2025. PMID: 39844393
Evaluation of Treatment Outcomes Using dNLR and GNRI in Combination Therapy With Atezolizumab and Bevacizumab for Hepatocellular Carcinoma.
Naganuma A, Kakizaki S, Hiraoka A, Tada T, Hatanaka T, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Toyoda H, Ogawa C, Nishikawa H, Nishimura T, Kawata K, Kosaka H, Hirooka M, Yata Y, Ohama H, Kuroda H, Matono T, Aoki T, Kanayama Y, Tanaka K, Tada F, Nouso K, Morishita A, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Nakamura S, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T. Naganuma A, et al. Among authors: ishikawa t. Cancer Med. 2025 Jan;14(2):e70618. doi: 10.1002/cam4.70618. Cancer Med. 2025. PMID: 39840727 Free article.
7,840 results